This risk is - this doesn’t get fast track approval and it falls back 20 -40% down to around 5-7c ( consider progress with BIT 225)
Or it gets fast track approval and SP goes up minimum 100% that day and would likely have MC that resembles something like RAC as study starts 50c -60c (500-600%+)
At that point it would be very risky that a early buyout offer is made .
If proven effective and FDA approved well then I would say there would be extreme risk of a multi billion dollar deal.
But before you start rambling on about warnings of slow reports and just warning of likely failure.
Biotron had never been in a better position before particularly with Covid in terms of being well placed to have a drug with an existing strong safety profile to be fast tracked into a human study. I think it would be risky to not have a parcel of shares here as it’s likely next announcement you could be paying over double.
BIT Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
